These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 16534589)
1. Valganciclovir for treatment of congenital cytomegalovirus infection. Schulzke S; Bührer C Eur J Pediatr; 2006 Aug; 165(8):575-6. PubMed ID: 16534589 [No Abstract] [Full Text] [Related]
2. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Galli L; Novelli A; Chiappini E; Gervaso P; Cassetta MI; Fallani S; de Martino M Pediatr Infect Dis J; 2007 May; 26(5):451-3. PubMed ID: 17468661 [TBL] [Abstract][Full Text] [Related]
3. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Amir J; Wolf DG; Levy I Eur J Pediatr; 2010 Sep; 169(9):1061-7. PubMed ID: 20232081 [TBL] [Abstract][Full Text] [Related]
4. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection. Yilmaz Çiftdogan D; Vardar F J Trop Pediatr; 2011 Apr; 57(2):132-4. PubMed ID: 20576693 [TBL] [Abstract][Full Text] [Related]
5. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW; Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. Kimberlin DW; Acosta EP; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud GA; Lakeman FD; Whitley RJ; J Infect Dis; 2008 Mar; 197(6):836-45. PubMed ID: 18279073 [TBL] [Abstract][Full Text] [Related]
7. [Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?]. Sola E; Vega E; Gutiérrez C; López V; Cabello M; Burgos D; González Molina M; Siles J Nefrologia; 2009; 29(2):180-1. PubMed ID: 19396331 [No Abstract] [Full Text] [Related]
9. Ganciclovir therapy for neonates with congenital cytomegalovirus infection. Luck S; Sharland M; Griffiths P Eur J Pediatr; 2007 Jun; 166(6):633-4. PubMed ID: 17043842 [No Abstract] [Full Text] [Related]
10. Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection. Natale F; Bizzarri B; Cardi V; Gaeta A; Villani P; Liuzzi G; De Curtis M Ital J Pediatr; 2015 Mar; 41():26. PubMed ID: 25888518 [TBL] [Abstract][Full Text] [Related]
11. Oral Valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age. Hilgendorff A; Daiminger A; Dangel V; Kreuder J; Geidel C; Reiss I; Enders G Klin Padiatr; 2009 Dec; 221(7):448-9. PubMed ID: 20013570 [No Abstract] [Full Text] [Related]
12. [Valganciclovir. Oral treatment of Cytomegalovirus infections]. Kroes AC Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386 [TBL] [Abstract][Full Text] [Related]
13. Symptomatic congenital Cytomegalovirus deafness: the impact of a six-week course of antiviral treatment on hearing improvement. Mazzaferri F; Cordioli M; Conti M; Storato S; Be G; Biban P; Concia E; Merighi M Infez Med; 2017 Dec; 25(4):347-350. PubMed ID: 29286014 [TBL] [Abstract][Full Text] [Related]
14. [Prolonged treatment with valganciclovir in an infant with congenital cytomegalovirus infection]. Baquero-Artigao F; Romero Gómez MP An Pediatr (Barc); 2009 Jun; 70(6):578-81. PubMed ID: 19423406 [TBL] [Abstract][Full Text] [Related]
15. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ; N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271 [TBL] [Abstract][Full Text] [Related]
16. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. Humar A; Siegal D; Moussa G; Kumar D J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456 [TBL] [Abstract][Full Text] [Related]
17. Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. Kimberlin DW; Aban I; Peri K; Nishikawa JK; Bernatoniene J; Emonts M; Klein N; Bamford A; DeBiasi RL; Faust SN; Jones CE; McMaster P; Caserta M; Ahmed A; Sharland M; Demmler-Harrison G; Hackett S; Sánchez PJ; Shackley F; Kelly D; Dennehy PH; Storch GA; Whitley RJ; Griffiths P; J Pediatr; 2024 May; 268():113934. PubMed ID: 38309519 [TBL] [Abstract][Full Text] [Related]
18. Ganciclovir for the treatment of congenital cytomegalovirus: what are the side effects? Gwee A; Curtis N; Connell TG; Garland S; Daley AJ Pediatr Infect Dis J; 2014 Jan; 33(1):115. PubMed ID: 24346602 [No Abstract] [Full Text] [Related]
20. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved? Avery RK Am J Transplant; 2007 Sep; 7(9):2062-3. PubMed ID: 17697259 [No Abstract] [Full Text] [Related] [Next] [New Search]